|
1）Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006; 6: 714-27
|
|
|
|
2）Gelderman KA, Tomlinson S, Ross GD, et al. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 2004; 25: 158-64
|
|
|
|
|
3）Selenko N, Maidic O, Draxier S, et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8＋ cytotoxic T cells. Leukemia. 2001; 15: 1619-26
|
|
|
|
|
|
4）Dhodapkar KM, Krasovsky J, Williamson B, et al. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med. 2002; 195: 125-33
|
|
|
|
|
|
5）zum Buschenfelde CM, Hermann C, Schmidt B, et al. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res. 2002; 62: 2244-7
|
|
|
|
|
|
6）Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003; 22: 7359-68
|
|
|
|
|
|
7）Hinoda Y, Sasaki S, Ishida T, et al. Monoclonal antibodies as effective therapeutic agents for solid tumors. Cancer Sci. 2004; 95: 621-5
|
|
|
|
|
8）Ashkenazi A. Targeting death and decoy receptors of the tumor-necrosis factor superfamily. Nat Rev Cancer. 2002; 2: 420-30
|
|
|
|
|
|
9）Creagan ET, Kovach JS, Moertel CG, et al. A phase I clinical trial of recombinant human tumor necrosis factor. Cancer. 1998; 62: 2467- 71
|
|
|
|
|
|
10）Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature. 1993; 364: 806-9
|
|
|
|
|
|
11）Smyth MJ, Takeda K, Hayakawa Y, et al. Nature's TRAIL--on a path to cancer immunotherapy. Immunity. 2003; 18: 1-6
|
|
|
|
|
|
12）Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995; 3: 673-82
|
|
|
|
|
|
13）Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996; 271: 12687-90
|
|
|
|
|
|
14）Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999; 5: 157-63
|
|
|
|
|
|
15）Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999; 104: 155-62
|
|
|
|
|
|
16）Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med. 2002; 195: 161-9
|
|
|
|
|
|
17）Cretney E, Takeda K, Yagita H, et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol. 2002; 168: 1356-61
|
|
|
|
|
|
18）Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21: 137-48
|
|
|
|
|
|
19）Schneider P, Olson D, Tardivel A, et al. Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem. 2003; 278: 5444-54
|
|
|
|
|
|
20）Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997; 277: 818-21
|
|
|
|
|
|
21）Mori E, Thomas M, Motoki K, et al. Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ. 2004; 11: 203-7
|
|
|
|
|
|
22）Hayakawa Y, Screpanti V, Yagita H, et al. NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J Immunol. 2004; 172: 123-9
|
|
|
|
|
|
23）Chuntharapai A, Dodge K, Grimmer K, et al. Isotype-dpendent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol. 2001; 166: 4891-8
|
|
|
|
|
|
24）Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med. 2001; 7: 954-60
|
|
|
|
|
|
25）Takeda K, Yamaguchi N, Akiba H, et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med. 2004; 199: 437-48
|
|
|
|
|
|
26）Rowinsky EK. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol. 2005; 23: 9394-407
|
|
|
|
|
|
27）LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003; 10: 66-75
|
|
|
|
|
|
28）Yagita H, Takeda K, Hayakawa Y, et al. TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 2004; 95: 777-83
|
|
|
|
|
|
29）Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999; 5: 677-85
|
|
|
|
|
|
30）Allison JP, Hurwitz AA, Leach DR. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol. 1995; 7: 682-6
|
|
|
|
|
|
31）Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity？ Nat Rev Immunol. 2003; 3: 609-20
|
|
|
|
|
|
32）Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007; 7: 95-106
|
|
|
|
|
|
33）Diehl L, den Boer AT, Schoenberger SP, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med. 1999; 5: 774-9
|
|
|
|
|
|
34）French RR, Chan HT, Tutt AL, et al. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med. 1999; 5: 548-53
|
|
|
|
|
|
35）Sotomayor EM, Borrello I, Tubb E, et al. Conversion of tumor-specific CD4＋ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med. 1999; 5: 780-7
|
|
|
|
|
|
36）Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997; 3: 682-5
|
|
|
|
|
|
37）Uno T, Takeda K, Kojima Y, et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med. 2006; 12: 693-8
|
|
|
|
|
|
38）Basombrio MA. Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene. Cancer Res. 1970; 30: 2458-62
|
|
|
|
|
|
39）Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape" phenotypes. Nat Immunol. 2002; 3: 999-1005
|
|
|
|
|
|
40）Takeda K, Stagg J, Yagita H, et al. Trageting death-inducing receptors in cancer therapy. Oncogene. 2007; 26: 3745-57
|
|
|
|
|
|
41）Takeda K, Okumura K, Smyth MJ. Combination antibody-based cancer immunotherapy. Cancer Sci. 2007; 98: 1297-302
|
|
|
|
|